[A19-04] Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V
Last updated 17.10.2024
Project no.:
A19-04
Commission:
Commission awarded on 11.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Insomnia in children and adolescents with Autism Spectrum Disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
Added benefit not proven due to lack of informative study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-47 | Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04 | Commission completed |
Federal Joint Committee (G-BA)
17 October 2024: The G-BA’s decision of 4 July 2019 was cancelled.
G-BA documents on this decision